Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Jonathan W. Friedberg(University of Rochester), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Carrie A. Thompson(Mayo Clinic), Amitkumar Mehta(University of Alabama at Birmingham), Catherine Thiéblemont(Université Paris Cité), Bei Hu(Levine Cancer Institute), Avrita Campinha‐Bacote, Franck Morschhauser(Hôpital Claude Huriez), Piotr Smolewski(Medical University of Lodz), Jamie Hirata(Universidad San Carlos), Maurizio Martelli(University of Milan), Mark Hertzberg(The University of Sydney), Patrick M. Reagan(University of Rochester), Gilles Salles(Memorial Sloan Kettering Cancer Center), Marek Trněný(Charles University), Calvin Lee, Gustavo Fonseca(Sarah Cannon), Won-Seog Kim(Samsung Medical Center), Matthew Sugidono(University of California, San Francisco), Mark Yan(Roche (Canada)), Huilai Zhang(Shanxi Medical University)
Cited by 6
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782